SLFN11

ProLynx announces initiation of Phase I/II clinical trial of its DNA-damaging agent PLX038 in patients with rare CNS tumors at the National Cancer Institute (NCI)

Retrieved on: 
måndag, februari 5, 2024
MYCN, Toxicity, SAN, Neoplasm, NCI, Glomus tumor, SN-38, DNA, Cmax, SLFN11, Clinical trial, Gene, Biomarker, Cell division, Patient, Safety, Irinotecan, Pros, Central nervous system, MYC, PEGylation, CNS, Phase, Medulloblastoma, TTY, Cancer, Bangladesh Technical Education Board, Ependymoma, Pharmaceutical industry

National Institutes of Health’s NCI investigators Dr. Marta Penas-Prado and Dr. Mark Gilbert are conducting the trial.

Key Points: 
  • National Institutes of Health’s NCI investigators Dr. Marta Penas-Prado and Dr. Mark Gilbert are conducting the trial.
  • High levels of MYC drive oncogenesis in many cancers and induce DNA changes leading to the formation of “topoisome complexes”.
  • The NCI trial will assess whether PLX038 is safe and efficacious in primary CNS tumors driven by MYC or MYCN amplifications.
  • For patients interested in enrolling in this clinical trial, please call NCI’s toll-free number: 1-800-4-Cancer (1-800-422-6237) (TTY: 1-800-332-8615); visit the website: https://trials.cancer.gov; and/or email: [email protected].

Jazz Pharmaceuticals to Present Data at 2023 AACR Annual Meeting Showcasing New Zepzelca® (lurbinectedin) Data and Expanded Oncology Pre-Clinical and Clinical Pipeline

Retrieved on: 
onsdag, mars 15, 2023
Research, American Association for Cancer Research, AACR, DNA, Jazz Pharmaceuticals, RNA, SCLC, Abstract, SLFN11, Vaccine

DUBLIN, March 15, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present five new abstracts at the American Association for Cancer Research (AACR) Annual Meeting from April 14-19, 2023.

Key Points: 
  • DUBLIN, March 15, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present five new abstracts at the American Association for Cancer Research (AACR) Annual Meeting from April 14-19, 2023.
  • Research findings to be presented include data from company-sponsored and collaborative trials studying Zepzelca® (lurbinectedin), zanidatamab and JZP898.
  • Data highlights at the AACR Annual Meeting include:
    A poster presentation evaluating the role of SLFN11 expression in predicting response to lurbinectedin, a DNA damaging agent, in human small cell lung cancer (SCLC) cell lines and in vivo models.
  • Results demonstrate that efficacy may be correlated to SLFN11 protein expression, consistent with the RNA level association.1
    The AACR abstracts are available at: https://www.abstractsonline.com/pp8/#!/10828/
    The full list of Jazz-supported presentations at the 2023 AACR Annual Meeting are:

ProLynx announces initiation of Phase II clinical trial of its DNA-damaging agent PLX038 in patients with platinum-resistant Ovarian Cancer at the Mayo Clinic

Retrieved on: 
fredag, oktober 7, 2022
SAN, CA, ATM, PARP, Mayo Clinic, Clinical professor, Neoplasm, Woman, Mayo, Patient, Biotechnology, Carboplatin, RAD51, Hendrickson, DRS, Pharmacokinetics, PEG, Safety, Recurrence, Protein, GLOBE, Clinical trial, SLFN11, Death, Peptide, SN-38, Ovarian cancer, Biomarker, Pharmaceutical industry, Medical imaging, Irinotecan

SAN FRANCISCO, Oct. 07, 2022 (GLOBE NEWSWIRE) -- ProLynx Inc. today announced that the first patient was treated with PLX038 (PEG~SN-38) in a Phase II clinical trial for platinum-resistant ovarian cancer at the Mayo Clinic.

Key Points: 
  • SAN FRANCISCO, Oct. 07, 2022 (GLOBE NEWSWIRE) -- ProLynx Inc. today announced that the first patient was treated with PLX038 (PEG~SN-38) in a Phase II clinical trial for platinum-resistant ovarian cancer at the Mayo Clinic.
  • Carboplatin responses become shorter with each recurrence, and in platinum-resistant ovarian cancer the response rate to subsequent agents is only 15- to 20%.
  • Previous studies have shown that conventional inhibitors of the enzyme topoisomerase 1 have clinical activity in platinum-resistant ovarian cancer, and the Mayo trial seeks to improve this activity with the new PLX038.
  • Added ProLynx co-founder and President Daniel V. Santi Conventional short-acting topoisomerase 1 inhibitors have clinical activity in platinum-resistant ovarian cancer.

2021 Insights on Small Cell Lung Cancer - 10-year Epidemiological Forecast - ResearchAndMarkets.com

Retrieved on: 
måndag, november 15, 2021
Health, Oncology, Population, Squamous cell carcinoma, Lung cancer, SLFN11, Organizing, Chest pain, Sex, Doctor of Philosophy, AGR, Risk, Epidemiology, SCLC, Targeted therapy of lung cancer, Breathe Me, Incidence, Hemoptysis, Therapy, Cough, Smoking, Diagnosis, Weight loss, Survival, Prevalence, Patient, Death, Uranium, Medical imaging, Dietary supplement, Management, Pharmaceutical industry

The "Small Cell Lung Cancer - Epidemiology Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Small Cell Lung Cancer - Epidemiology Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.
  • SCLC is an aggressive form of lung cancer where approximately 60-70% of patients already have distant metastasis at presentation.
  • Small Cell Lung Cancer (SCLC) Epidemiology Report provides an overview of the risk factors and global trends of SCLC in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Urban China).
  • 2 Small Cell Lung Cancer: Executive Summary